Moderna prepares for Q4 printing; this is the latest prediction from Wall Street’s most accurate analysts – Moderna (NASDAQ: mRNA)

Moderna, Inc. mRNA Its fourth-quarter financial results will be released on Friday, February 14, 2025.

Analysts expect the Cambridge, Massachusetts-based company to report quarterly losses of $2.68 per share, compared with annual revenue of 55 cents per share. According to Benzinga Pro, the ModernA project’s quarterly revenue was $942.84 million, compared with $2.81 billion in the same period last year.

The company has the highest consensus estimates at the top and bottom lines for four consecutive quarters.

Hyundai shares rose 4.5% to close at $31.92 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Inventory Ratings page. Readers can sort by stock, company name, analyst company, rating changes, or other variables.

Let’s see how Benzinga’s most accurate analysts have evaluated the company in recent times.

• Securities analyst Tim Anderson’s B cuts its target to $34 on February 11, 2025. The analyst has a 62% accuracy rate.
• Cory Kaimov, an analyst at Evercore ISI Group, kept his target target online on January 27, 2025 and lowered his target target from $60 to $50. The analyst has a 69% accuracy rate.
• Argus Research analyst John Eade lowered the stock from buying to holding on December 18, 2024. The analyst has a 74% accuracy rate.
• JP Morgan analyst Jessica Fye maintained his underweight rating and lowered his target to $45 from $59 on November 26, 2024. The analyst has a 62% accuracy rate.

Consider buying mRNA stocks? Analysts believe:

Read this next: